% | $
Quotes you view appear here for quick access.

Array BioPharma Inc. Message Board

  • dcaf7 dcaf7 May 6, 2013 4:57 PM Flag

    New trial of MEK 162 in ovarian cancer

    Array is going to jump from phase 1 to phase 3. How wise it is? And their phase 1 includes MEK 162 plus paclitaxel. No paclitaxel is mentioned in proposed phase 3. Although selumetinib did show good results in Phase 2 study, MEK 162 is a different compound.

3.7575-0.0125(-0.33%)2:52 PMEDT